Compared to normal tissue, GLO-1 was significantly upregulated in 28 tumors, including GBM (Tumor: 6.73 0.48, Normal: 5.37 1.31, p = 6.7e75), GBMLGG (Tumor: 6.58 0.41, Normal: 5.37 1.31, p = 8.5e216), LGG (Tumor: 6.53 0.37, Normal: 5.37 1.31, p = 3.7e178), BRCA (Tumor: 6.83 0.68, Normal: 5.37 1.31, p = 3.7e179), EGFR (Tumor: 6.83 0.68, Normal: 5.37 1.31, p = 3.7e179), CESC (Tumor: 6.44 0.63, Normal: 5.91 0.21, p = 1.2e4), LUAD (Tumor: 6.49 0.68, Normal: 5.87 0.93, p = 3.5e42), ESCA (Tumor: 6.78 0.62, Normal: 5.25 1.26, p = 6.3e84), STES (Tumor: 6.44 0.68, Normal: 5.13 1.38, p = 3.6e165), COAD (Tumor: 6.40 0.52, Normal: 4.99 1.67, p = 2.6e90), COADREAD (Tumor: 6.43 0.55, Normal: 5.01 1.66, p = 1.9e102), PRAD (Tumor: 7.81 0.90, Normal: 6.52 1.03, p = 4.7e34), STAD (Tumor: 6.29 0.65, Normal: 4.75 1.64, p = 6.8e64), HNSC (Tumor: 6.49 0.60, Normal: 5.72 0.54, p = 9.7e15), LUSC (Tumor: 6.52 0.66, Normal: 5.87 0.93, p = 9.2e48), LIHC (Tumor: 5.86 0.76, Normal: 4.87 0.60, p = 9.8e38), WT (Tumor: 7.21 0.38, Normal: 6.07 1.49, p = 3.5e35), SKCM (Tumor: 6.14 0.83, Normal: 5.78 0.39, p = 4.1e11), BLCA (Tumor: 6.13 0.74, Normal: 5.78 0.33, p = 1.3e3), THCA (Tumor: 5.64 0.43, Normal: 5.29 0.92, p = 7.8e28), READ (Tumor: 6.50 0.62, Normal: 6.02 0.34, p = 4.8e3), OV (Tumor: 6.59 1.08, Normal: 6.11 0.26, p = 5.6e14), PAAD (Tumor: 5.58 0.46, Normal: 3.62 1.58, p = 1.0e53), TGCT (Tumor: 6.01 0.89, Normal: 4.47 0.63, p = 1.3e37), and UCS (Tumor: 6.72 0.60, Normal: 5.74 0.29, p = 5.2e-18)
Take 1 tablet per day on an empty stomach or as directed by your qualified healthcare professional
This phenomenon is called the "bloodbraintumor barrier," and it can block chemotherapy agents from reaching tumor lesions and offer a barrier to the treatment of CNS tumors ( Fig
S., Brcic, L., et al
